REED JOHN C
SEC Form 4 insider trading activity
REED JOHN C has filed 4 SEC Form 4 filings (14 transaction rows) across 2 companies, including MDGL, JNJ, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Aug 18, 2026.
On the most recent filing, REED JOHN C is listed as EVP, Innovative Medicine, R&D at JOHNSON & JOHNSON. Inside the rolling window, REED JOHN C reported no open-market purchases and 1 open-market sale totaling $13.1M in JNJ.
Companies traded
Other insiders at MDGL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$13.1M
reported sales (SEC code S)
Companies
2
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Oct 17, 2025 | JNJ | Sale | $4.2M |
Frequently asked questions
How many SEC Form 4 filings has REED JOHN C made?
REED JOHN C has filed 4 SEC Form 4 filings (14 transaction rows) across 2 companies, including MDGL, JNJ since 2025.
Which companies does REED JOHN C trade?
REED JOHN C has filed SEC Form 4 disclosures for 2 companies, including MDGL, JNJ.
When was REED JOHN C's most recent SEC Form 4 filing?
REED JOHN C's most recent SEC Form 4 filing on Tracefour is dated Aug 18, 2026.
What is REED JOHN C's total buy and sell value in the current window?
Inside the rolling retention window, REED JOHN C bought $0 and sold $13.1M based on SEC Form 4 filings.
What was REED JOHN C's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 53,931 JNJ shares on 2026-02-17, worth $13.1M, per SEC Form 4 filings.